You sound like you just started for first time on biotech stocks!!!
RIGL is like any typical speculative biotech stock. They raise money thru selling stock over time while they are in development stages... thus 'speculative. All that matters with a stock like this if you are short term trading the swings, is that they have cash for 1+ year. RIGL has solid cash thru mid-2016, so RUGL in good shape. You are spewing hot air over a futile, useless issue. Their cash is great for now, so focus on 2nd half of 2014, etc, for catalysts such as drug news developments.
Could a breakout occur for REVI now that it has sewn up the JV deal with Hemp Inc. for the publication of Hemp Nation magazine? Wall Street seems to think so
Why analysts believe that PLWY can shatter .18 ceiling and potentially reach $1.50. Bullish expectations being driven by latest Idea Webcatchers acquisition
MEDA expects to grow its user base and profits from the technology hub of the world. Move to 800 West El Camino Real, Mountain View, CA confirmed
MEDA could take over analytics market after news announced that Klarity launched a TencentWeibo analytics app integration for HootSuite
DEQI outlines blockbuster mobile game launch based on record-breaking film created by the same company behind Star Wars. Growth potential tipped to explode.
Could Gem Smasher become the game that takes DEQI into the $60 billion sector for social gaming? Management unveils major plans to expand distribution of latest acquisition
I bought in because a nurse that worked for a doctor that was administering the clinical testing for RA said her daughter was having dramatic improvements... and then that failed. I stayed in because of the pipeline which now has another failure. Fostamatinib - ITP is the only near-term hope for a price increase, but for the life of me, I don't understand why some of the science from the RA drug can't be re-investigated as I saw first hand what occurred in this one patient. oh well, keep yer helmet on
I see that all future quarters are losing cash, and with $2 per share cash twindling away I have a simple question:
Where is more cash going to come from for RIGL?
I see no assets they can sell.
So, is it expected that cash per share of $2 will drop and drop and drop?
Where is the turn around to profits, years out?
Very important information needed. If this is all true then this share price can actually go to $2 and even under if forward guided losses are factored in. ~$1.80 would be possible
Algae bloom cripples Toledo’s water supplies as 500,000 people are left without safe drinking water. Massive calls for innovative solutions turns spotlight onto OGNG
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy